Women who endure migraine are more susceptible to the development of obstetric and postpartum complications when pregnant, according to study results.
Pregnant women with migraine are at an increased risk of developing obstetric and postpartum complications compared with unaffected women, according to a study presented at the 7th Congress of the European Academy of Neurology.
Researchers reviewed pregnancy and delivery records from a database of Clahit Health Medical Organization in Israel, and assessed data on demographics, mode of delivery, and medical and obstetric complications in each pregnancy trimester. They also looked at use of medications and repeated medical consultations. The study enrolled 161,574 women who gave birth between 2014 and 2019.
The 8723 women who were diagnosed with migraine experienced a higher risk of obstetric complications and postpartum depression compared with the 152,851 women in the control group. Furthermore, pregnant women with migraine were more likely to be admitted to high-risk departments. This rate was 6% for healthy pregnant women, 6.9% for migraineurs without aura, and 8.7% for those with migraine with aura.
Findings also showed pregnant migraineurs:
Authors recommended pregnant women with migraine receive high-risk pregnancy protocol of care during their pregnancy due to their heightened susceptibility to obstetric and medical complications. These patients should also complete neurological follow-ups throughout pregnancy and during their postpartum recovery.
Migraine affects more than 10% of people and is one of the most prevalent neurological disorders worldwide. In addition, women are 3 times more likely to be diagnosed with migraine than men, while menstruation, menopause, and childbirth have been shown to induce hormonal changes that can lead to worsened migraine activity.
Reference
Lev N, and Elefant E. Migraine in pregnancy and postpartum epidemiological and clinical characteristics. Presented at: 7th Congress of the European Academy of Neurology; June 19-22, 2021. Abstract OPR-066.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen